Pedro M Rodríguez Cruz1, Michal Al-Hajjar2, Saif Huda2, Leslie Jacobson2, Mark Woodhall2, Sandeep Jayawant3, Camilla Buckley2, David Hilton-Jones2, David Beeson4, Angela Vincent2, Maria Isabel Leite2, Jacqueline Palace2. 1. Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, England2Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, England. 2. Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, England. 3. Department of Paediatric Neurology, Children's Hospital, John Radcliffe Hospital, Oxford, England. 4. Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, England.
Abstract
IMPORTANCE: Cell-based assays (CBAs) were shown to improve detection of acetylcholine receptor (AChR) antibodies in patients with myasthenia gravis (MG). Herein, we asked whether these assays were able to help determine the diagnosis in patients studied in routine clinical practice. OBJECTIVES: To determine the diagnostic usefulness of CBAs in the diagnosis of MG and to compare the clinical features of patients with antibodies only to clustered AChRs with those of patients with seronegative MG (SNMG). DESIGN, SETTING, AND PARTICIPANTS: All patients with clinical suspicion of MG who were seen within the Division of Clinical Neurology at the John Radcliffe Hospital in Oxford, England, between November 1, 2009, and November 30, 2013. Their serum antibodies and clinical features were studied. EXPOSURES: Radioimmunoprecipitation assay (RIPA) and CBA were used to test for standard AChR antibodies and antibodies to clustered AChRs in 138 patients. All available samples from patients with SNMG were retrospectively tested for lipoprotein receptor-related protein 4 (LRP4) antibodies. MAIN OUTCOMES AND MEASURES: Demographic, clinical, neurophysiological, and laboratory data. RESULTS: In total, 138 patients were tested for antibodies to clustered AChRs, and 42 had a final diagnosis of MG. The clustered AChR CBA detected antibodies in 38.1% (16 of 42) of RIPA-negative patients with MG with 100% specificity. All patients with SNMG who were tested for LRP4 antibodies (21 of 26) were negative by CBA. Compared with patients with SNMG, patients with antibodies only to clustered AChRs had frequent prepubertal onset (62.5% [median age, 6 years; age range, 1-52 years] vs 11.5% [median age, 38 years; age range, 2-72 years], P ≤ .05), high prevalence of ocular MG (62.5% vs 42.3%), milder disease severity with less bulbar involvement (25.0% vs 46.2%), and absence of respiratory symptoms (0% vs 23.1%). Response to treatment and prognosis was good, with a reduced need for thymectomy (6.3% vs 19.2%) and a high proportion of patients going into remission (50.0% vs 8.3%, P ≤ .05). These observations also apply to the classic AChR MG phenotype seen in large series. CONCLUSIONS AND RELEVANCE: Cell-based assay is a useful procedure in the routine diagnosis of RIPA-negative MG, particularly in children. Patients with antibodies only to clustered AChRs appear to be younger and have milder disease than other patients with MG. These observations will have implications in planning treatment.
IMPORTANCE: Cell-based assays (CBAs) were shown to improve detection of acetylcholine receptor (AChR) antibodies in patients with myasthenia gravis (MG). Herein, we asked whether these assays were able to help determine the diagnosis in patients studied in routine clinical practice. OBJECTIVES: To determine the diagnostic usefulness of CBAs in the diagnosis of MG and to compare the clinical features of patients with antibodies only to clustered AChRs with those of patients with seronegative MG (SNMG). DESIGN, SETTING, AND PARTICIPANTS: All patients with clinical suspicion of MG who were seen within the Division of Clinical Neurology at the John Radcliffe Hospital in Oxford, England, between November 1, 2009, and November 30, 2013. Their serum antibodies and clinical features were studied. EXPOSURES: Radioimmunoprecipitation assay (RIPA) and CBA were used to test for standard AChR antibodies and antibodies to clustered AChRs in 138 patients. All available samples from patients with SNMG were retrospectively tested for lipoprotein receptor-related protein 4 (LRP4) antibodies. MAIN OUTCOMES AND MEASURES: Demographic, clinical, neurophysiological, and laboratory data. RESULTS: In total, 138 patients were tested for antibodies to clustered AChRs, and 42 had a final diagnosis of MG. The clustered AChR CBA detected antibodies in 38.1% (16 of 42) of RIPA-negative patients with MG with 100% specificity. All patients with SNMG who were tested for LRP4 antibodies (21 of 26) were negative by CBA. Compared with patients with SNMG, patients with antibodies only to clustered AChRs had frequent prepubertal onset (62.5% [median age, 6 years; age range, 1-52 years] vs 11.5% [median age, 38 years; age range, 2-72 years], P ≤ .05), high prevalence of ocular MG (62.5% vs 42.3%), milder disease severity with less bulbar involvement (25.0% vs 46.2%), and absence of respiratory symptoms (0% vs 23.1%). Response to treatment and prognosis was good, with a reduced need for thymectomy (6.3% vs 19.2%) and a high proportion of patients going into remission (50.0% vs 8.3%, P ≤ .05). These observations also apply to the classic AChR MG phenotype seen in large series. CONCLUSIONS AND RELEVANCE: Cell-based assay is a useful procedure in the routine diagnosis of RIPA-negative MG, particularly in children. Patients with antibodies only to clustered AChRs appear to be younger and have milder disease than other patients with MG. These observations will have implications in planning treatment.
Authors: E Beghi; C Antozzi; A P Batocchi; F Cornelio; V Cosi; A Evoli; M Lombardi; R Mantegazza; M L Monticelli; G Piccolo Journal: J Neurol Sci Date: 1991-12 Impact factor: 3.181
Authors: Thashi Chang; Maria Isabel Leite; Sunethra Senanayake; Padma S Gunaratne; Ranjanie Gamage; M T M Riffsy; Leslie W Jacobson; Madura Adhikari; Sanja Perera; Angela Vincent Journal: J Neurol Sci Date: 2014-05-27 Impact factor: 3.181
Authors: Jeremy Ross Parr; Morag Jane Andrew; Maria Finnis; David Beeson; Angela Vincent; Sandeep Jayawant Journal: Arch Dis Child Date: 2014-02-05 Impact factor: 3.791
Authors: Judith Cossins; Katsiaryna Belaya; Katarzyna Zoltowska; Inga Koneczny; Susan Maxwell; Leslie Jacobson; Maria Isabel Leite; Patrick Waters; Angela Vincent; David Beeson Journal: Ann N Y Acad Sci Date: 2012-12 Impact factor: 5.691
Authors: Isabell Cordts; Nicolas Bodart; Kathi Hartmann; Katerina Karagiorgou; John S Tzartos; Lin Mei; Jens Reimann; Philip Van Damme; Michael H Rivner; Alain Vigneron; Joachim Weis; Jörg B Schulz; Socrates J Tzartos; Kristl G Claeys Journal: J Neurol Date: 2017-05-17 Impact factor: 4.849
Authors: Yonghao Cao; Robert A Amezquita; Steven H Kleinstein; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor Journal: J Immunol Date: 2016-01-29 Impact factor: 5.422
Authors: Saif Huda; Patrick Waters; Mark Woodhall; Maria Isabel Leite; Leslie Jacobson; Anna De Rosa; Michelangelo Maestri; Roberta Ricciardi; Jeannine M Heckmann; Angelina Maniaol; Amelia Evoli; Judy Cossins; David Hilton-Jones; Angela Vincent Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-06-05